The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment with anti-spike monoclonal antibodies in allogeneic HCT and CAR T-cell recipients with mild to moderate COVID-19: The Mayo Clinic experience.
 
Razan Mohty
No Relationships to Disclose
 
Matthew Thoendel
No Relationships to Disclose
 
Samuel Swei
No Relationships to Disclose
 
Radhika Bansal
No Relationships to Disclose
 
Jeanne Palmer
No Relationships to Disclose
 
William J. Hogan
No Relationships to Disclose
 
Paschalis Vergidis
No Relationships to Disclose
 
Javier Munoz
Honoraria - Kyowa Hakko Kirin; Seagen
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Fosun Kite; Genentech; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Pfizer; Pharmacyclics; Seagen
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Madiha Iqbal
No Relationships to Disclose
 
Farah Yassine
No Relationships to Disclose
 
Nabila Nora Bennani
Consulting or Advisory Role - Affimed Therapeutics (Inst); Daiichi Sankyo (Inst); Kymera (Inst); Kyowa Kirin International (Inst); Purdue Pharma (Inst); Secura Bio (Inst); Verastem (Inst); Vividion Therapeutics (Inst)
Research Funding - Kite, a Gilead company (Inst)
 
Matthew Hathcock
No Relationships to Disclose
 
Hemant S. Murthy
Research Funding - crispr therapeutics (Inst)
 
Januario E. Castro
No Relationships to Disclose
 
Yi Lin
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gamida Cell (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Legend Biotech (Inst); Novartis (Inst); Pfizer (Inst); Sorrento Therapeutics (Inst); Vineti (Inst)
Research Funding - Bluebird Bio (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Merck (Inst); Takeda (Inst)
 
Raymund R. Razonable
No Relationships to Disclose
 
Mohamed Kharfan-Dabaja
Research Funding - Novartis